Business
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
HOUSTON, June 02, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya") today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intell
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"Patent protection strengthens Coya’s strategic and business development optionality","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"Coya and its partners are continuing to broaden and expand its rh IL-2 and rh IL-2 combination patent portfolio with ongoing filings and prosecutions","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"Coya is on track and plans to submit the IND for COYA 302 (a proprietary combination of the low dose-rhIL-2 + CTLA4-Ig) by the end of June supporting the initiation of the Phase 2b study in patients with ALS","length":207,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, June 02, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya") today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.","length":619,"tagName":"p"},{"type":"text","content":"Arun Swaminathan, PhD, CEO of Coya added: "The issuance of this in-licensed patent sets a strong milestone in the history of Coya. Our investigational low-dose rhIL-2 (COYA 301) is a key asset of Coya’s pipeline. This patent serves as only one component of a growing, broader, and layered IP portfolio involving combinations with other biologics – such as Coya’s combinations with CTLA-4 Ig (COYA 302) and GLP-1 agonists (COYA 303) that we believe, adds a broader moat of protection to the portfolio. We plan to continue to expand and enhance the IP portfolio."","length":571,"tagName":"p"},{"type":"text","content":"COYA 301, COYA 302, and COYA 303 are each an investigational product candidate not yet approved by the U.S. Food and Drug Administration.","length":137,"tagName":"p"},{"type":"text","content":"About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advanta...